GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Volatility

Aprea Therapeutics (Aprea Therapeutics) Volatility : 87.73% (As of May. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-24), Aprea Therapeutics's Volatility is 87.73%.


Competitive Comparison of Aprea Therapeutics's Volatility

For the Biotechnology subindustry, Aprea Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprea Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Volatility falls into.



Aprea Therapeutics  (NAS:APRE) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprea Therapeutics  (NAS:APRE) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Aprea Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics (Aprea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Aprea Therapeutics (Aprea Therapeutics) Headlines

From GuruFocus

Aprea Therapeutics Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 02-22-2023